BioInvent receives IND approval for Phase I/IIa trial of anti-TNFR2 antibody BI-1808 ...Middle East

LUND, Sweden, April 7, 2021 /PRNewswire/ -- BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV) today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) for the Phase I/IIa clinical study of the immuno-modulatory...

Hence then, the article about bioinvent receives ind approval for phase i iia trial of anti tnfr2 antibody bi 1808 was published today ( Wednesday 07/04/2021 - 10:01 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( BioInvent receives IND approval for Phase I/IIa trial of anti-TNFR2 antibody BI-1808 )

Also on site :

• '80s Hard Rock Band Announces Massive 2026 Tour With Iconic Special Guest
• LIVE: Villarreal vs Real Madrid – La Liga
• ‘The Traitors’ Issues Statement Addressing Bullying and Harassment of Cast Members